Calls for papers
-
The Japanese Ministry of Health, Labour and Welfare has approved Insmed’s Arikayce amikacin liposome inhalation suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC) in patients who have… Read more . . .
-
Altimmune announced that it has signed a manufacturing agreement with Summit Biosciences for a multidose version of Altimmune’s AdCOVID intranasal vaccine against COVID-19. The announcement comes shortly after Altimmune announced an agreement with Lonza for… Read more . . .
-
Copley Scientific has launched a new software package for cascade impactor management and data analysis called “Inhalytix,” which succeeds the company’s long-established CITDAS cascade impactor software. The new software, which is 21 CFR Part 11… Read more . . .
-
Sandoz said that the company has acquired distribution rights to the brand and to an authorized generic of Proventil HFA albuterol MDI from Kindeva Drug Delivery and has already launched the generic MDI in the US. Proventil… Read more . . .
-
Chiesi USA has announced the US launch of Bronchitol dry powder mannitol for the treatment of cystic fibrosis in adult patients. The FDA approved the Bronchitol DPI in November 2020. The company also announced the… Read more . . .
-
Galecto has announced that the company’s Phase 2b GALACTIC-1 study of GB0139 (formerly TD139) galectin-3 inhibitor DPI for the treatment of idiopathic pulmonary fibrosis (IPF) will discontinue the higher dose (10 mg) arm and will limit… Read more . . .
-
Meissa Vaccines announced that the FDA has cleared the company’s IND for a Phase 1 clinical study of its MV-014-212 intranasal live attenuated vaccine candidate against SARS-CoV-2. The company announced that it had held a pre-IND… Read more . . .
-
Ampio Pharmaceuticals said that preliminary results from its AP-014 Phase 1 clinical trial of inhaled Ampion for the treatment of COVID-19 demonstrate a significant reduction in all-cause mortality and shorter hospital stays for patients receiving Ampion… Read more . . .
-
In an expansion of a manufacturing agreement between Altimmune and Lonza that was announced in November 2020, Lonza has agreed to dedicate a manufacturing suite at its Texas facility for production of Altimmune’s AdCOVID intranasal… Read more . . .
-
Canadian biotech SaNOtize said that a Phase 2 trial of its nitric oxide nasal spray (NONS) in COVID-19 patients demonstrated that the nasal spray reduced viral load by about 95% within 24 hours post dose… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK